LifeStance Health Group, Inc. (NASDAQ:LFST) Stock Has Average Target Price of $12.88

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $13.12.

A number of analysts have recently commented on LFST shares. JPMorgan Chase & Co. lifted their price target on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Barclays increased their price objective on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, KeyCorp boosted their target price on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, October 5th.

Insider Activity at LifeStance Health Group

In related news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the completion of the sale, the insider owned 98,101,407 shares in the company, valued at approximately $1,041,836,942.34. This represents a 12.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Vukasin Paunovich sold 42,067 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the transaction, the chief technology officer directly owned 205,379 shares in the company, valued at approximately $2,643,227.73. This represents a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 13,777,580 shares of company stock worth $146,433,781. 3.50% of the stock is owned by insiders.

Hedge Funds Weigh In On LifeStance Health Group

A number of institutional investors and hedge funds have recently made changes to their positions in LFST. Silversmith Partners I GP LLC purchased a new stake in LifeStance Health Group during the fourth quarter valued at approximately $100,842,000. Bank of America Corp DE purchased a new position in shares of LifeStance Health Group during the 2nd quarter worth $14,987,000. Moran Wealth Management LLC bought a new stake in shares of LifeStance Health Group during the 1st quarter valued at $953,000. The Manufacturers Life Insurance Company bought a new stake in shares of LifeStance Health Group during the 2nd quarter valued at $966,000. Finally, Orbimed Advisors LLC purchased a new stake in shares of LifeStance Health Group in the 1st quarter worth $3,185,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Trading Up 3.0%

LifeStance Health Group stock opened at $12.42 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. LifeStance Health Group has a one year low of $4.77 and a one year high of $13.56. The stock has a market capitalization of $4.75 billion, a PE ratio of 95.55 and a beta of 1.24. The business’s fifty day moving average is $12.21 and its 200 day moving average is $9.76.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. The company had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%. LifeStance Health Group’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same period last year, the company earned ($0.01) EPS. On average, sell-side analysts predict that LifeStance Health Group will post 0.16 EPS for the current year.

About LifeStance Health Group

LifeStance Health Group, Inc is a U.S.-based healthcare company that provides outpatient mental health services through a network of clinicians. Its services are delivered through both in-person appointments and a virtual care platform, allowing patients to access care in a range of settings.

The company offers psychiatric evaluation and treatment, psychotherapy, medication management, psychological and neuropsychological testing, and related behavioral health services. LifeStance serves children, adolescents, and adults, addressing conditions such as anxiety, depression, attention-deficit/hyperactivity disorder, and other mental health and behavioral concerns.

LifeStance operates across multiple states in the United States and combines company-operated clinics with telehealth services.